GLP-1 Drugs Work. Here's Why You May Still Feel Stuck.

By Dr. Jay Wrigley, NMD — 30+ years of clinical practice in hormone and metabolic medicine

GLP-1 receptor agonists have become one of the most talked-about tools in metabolic health. For many people with type 2 diabetes or significant weight to lose, these medications produce real improvements in blood sugar control and body composition. Some patients report fewer cravings, more stable energy, and better lab numbers within weeks.

But a surprising number of people over 40 are discovering something that doesn't get discussed enough: even when the scale moves and glucose numbers improve, they still don't feel right. Energy stays inconsistent. Muscle feels harder to keep. Recovery is slow. Sleep remains fragile. And the underlying sense that their metabolism is "off" never fully resolves.

This isn't usually a failure of the medication. It's a signal that the medication is addressing one part of the problem — while the deeper hormonal and metabolic environment remains largely untouched.

That distinction matters more than most people realize. And it's why I want to walk through what GLP-1 drugs actually do, what they don't do, and what's really driving the metabolic resistance that makes blood sugar instability so persistent after 40.

How GLP-1 Drugs Actually Stabilize Blood Sugar

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. GLP-1 receptor agonists — medications like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) — mimic and extend that signal through several overlapping mechanisms.

They stimulate insulin release in a glucose-dependent way, meaning insulin rises primarily when blood sugar is already elevated. This is clinically significant because it avoids the dangerous lows that some older diabetes medications can cause. They also suppress glucagon — the hormone that signals the liver to release stored glucose into the bloodstream. In type 2 diabetes, glucagon is chronically overactive, so suppressing it reduces one major source of elevated fasting glucose.

Additionally, GLP-1 drugs slow gastric emptying. Food moves more gradually from the stomach into the small intestine, which flattens the post-meal glucose spike considerably. Combined with reduced appetite and lower overall food intake, the total glucose load the body has to process goes down.

The net effect is a smoother glucose curve: fewer spikes after meals, lower fasting blood sugar, and meaningful HbA1c reductions — often 1 to 2 percent or more in clinical trials. Some medications in this class also carry cardiovascular and kidney-protective benefits beyond glucose control, which adds to their clinical value for the right patient.

For the right person, these are legitimate, well-studied tools. The issue is never really whether they work on blood sugar. The issue is what they leave unchanged.

Why Many People Still Feel Stuck

After 40, blood sugar instability rarely exists in isolation. It almost always sits on top of several overlapping shifts in the hormonal and metabolic environment — shifts that have been building for years before any glucose problem becomes visible on a lab panel.

These include cortisol dysregulation, declining thyroid output and impaired T4-to-T3 conversion, progressive insulin resistance driven by hormonal changes rather than diet alone, loss of metabolically active muscle mass, disrupted sleep and circadian rhythm, and declining levels of estrogen, progesterone, and testosterone. These factors alter how the body handles glucose at a fundamental level. When they remain unaddressed, a GLP-1 can lower glucose numbers while the person still experiences energy crashes, stubborn visceral fat, poor recovery, and the persistent feeling that their body is working against them rather than with them.

The medication can move the number. It cannot, on its own, rebuild the metabolic terrain that made that number hard to control in the first place.

This is the gap I see most often in clinical practice. Someone takes a GLP-1, their A1c improves, their doctor is satisfied, and the patient is left wondering why they still feel metabolically exhausted. The medication did its job. The job just wasn't big enough.

The Other Incretin Most People Haven't Heard About

While GLP-1 gets most of the attention, there is a second major incretin hormone called GIP — glucose-dependent insulinotropic polypeptide. GIP is released from the small intestine after eating fat and carbohydrates, and it plays a meaningful role in insulin secretion, fat metabolism, appetite regulation, and bone health.

In obesity and type 2 diabetes, GIP receptor signaling is often disrupted. The body continues to receive the fat-storage signal from GIP, but loses the insulin-amplifying benefit. This is part of what makes the metabolic terrain in midlife so difficult to work with: the signals that should promote efficient glucose disposal start to fail, while the signals that promote fat storage keep working just fine.

This complexity is part of what made tirzepatide (Mounjaro, Zepbound) clinically notable. It activates both GIP and GLP-1 receptors simultaneously, and in head-to-head trials it outperformed GLP-1-only medications for both glucose control and weight loss. Most people on a GLP-1 alone are working with only half of the incretin equation.

But the critical point is not simply "more receptor activation is better." The critical point is that incretin signaling does not happen in a vacuum. It depends entirely on the metabolic terrain those receptors are operating in. Sleep quality, muscle mass, visceral fat levels, insulin resistance, cortisol rhythm, meal composition, chronic inflammation, and midlife hormone shifts all influence how effectively these signals transmit and how well the body responds to them. When that terrain is compromised, even medications designed to activate these receptors may not deliver their full expected benefit.

The GLP-1 Mistake Nobody Warns You About: Losing Weight While Losing the Signal

One of the most common and underappreciated problems I see with GLP-1 medications is the assumption that weight loss automatically means metabolic improvement. It does not — and the reason comes down to what kind of weight is being lost.

GLP-1 and dual GLP-1/GIP medications can reduce both fat mass and lean soft tissue. In several analyses of recent clinical trials, lean tissue loss has accounted for roughly 26 to 40 percent of total weight lost. This does not mean these medications destroy muscle. But it does mean muscle preservation cannot be treated as an afterthought.

After 40, this matters disproportionately. Muscle is one of the primary tissues responsible for taking up and clearing glucose after meals. It is a major driver of insulin sensitivity, metabolic flexibility, strength, thermoregulation, and long-term resilience. When someone loses a meaningful amount of muscle alongside fat, the foundation for stable blood sugar and sustained energy can actually weaken — even as the scale goes down and the A1c improves.

I've seen this pattern repeatedly in clinical practice. A patient takes a GLP-1, loses 20 pounds, and feels weaker, colder, more fatigued, and mentally flatter than before the medication. Their numbers look better. They feel worse. That is not usually a drug side effect. It is a signal that the metabolic foundation was not being rebuilt while the weight came off.

A GLP-1 may reduce appetite. It cannot tell your body which tissue to protect. That distinction requires a deliberate strategy.

This is where protein becomes non-negotiable. Adequate protein at meals provides the raw material for muscle repair and preservation. Resistance training signals the body to hold onto lean tissue under conditions of caloric reduction. Sleep and recovery regulate the stress chemistry that contributes to muscle breakdown in the first place. These are not optional additions to a GLP-1 protocol. For anyone over 40, they are the difference between losing weight and actually improving metabolic function.

How to Support the Terrain These Medications Depend On

Whether someone is taking a GLP-1 medication or trying to improve metabolic function without one, the same foundational inputs consistently drive better outcomes. These are not quick fixes. They are the conditions under which your body's own incretin signaling, insulin sensitivity, and hormonal regulation actually work.

Protein as the first metabolic signal. Adequate protein at each meal supports muscle retention, reduces hunger, and provides the structural raw materials for metabolic repair. In my clinical framework, protein is the primary lever — not just a macronutrient to fill in after carbohydrates and fat are accounted for. Most people over 40 are chronically under-consuming it, especially in the morning when it matters most for cortisol and blood sugar regulation throughout the day.

Resistance training. Muscle is a glucose-disposal organ. Building or preserving it improves insulin sensitivity in a way that no medication can fully replicate. Even two to three sessions per week of meaningful resistance work changes how the body partitions glucose and responds to incretin signals.

Sleep and circadian rhythm. Disrupted sleep impairs glucose regulation and incretin function directly. After 40, protecting sleep quality — both duration and architecture — often becomes one of the highest-leverage inputs in metabolic health. Cortisol dysregulation and blood sugar instability are frequently downstream of sleep disruption, not the other way around.

Reducing visceral fat while preserving lean tissue. Visceral fat is strongly linked to insulin resistance and disrupted incretin signaling. Sustainable fat loss that protects lean tissue tends to improve the overall hormonal and metabolic environment over time. The goal is not just a lower number on the scale — it's a better ratio of metabolically active tissue to stored fat.

Meal composition and eating order. Consuming protein and fat before carbohydrates at a meal meaningfully reduces the post-meal glucose spike. Reducing ultra-processed foods and keeping meal timing consistent lowers the background noise of glucose and insulin volatility that makes the rest of hormonal regulation harder.

Magnesium adequacy. Magnesium is a cofactor in insulin receptor signaling and is depleted by chronic stress, poor sleep, and excess insulin. Deficiency blunts the entire incretin cascade and is far more common in midlife adults than most clinicians screen for.

These inputs influence cortisol, thyroid function, insulin sensitivity, and sex hormone balance — the same upstream drivers that determine whether any medication or supplement can actually do its job effectively.

Pattern First. Tools Second.

The conversation around GLP-1 medications tends to center on a single question: should someone take them or not? That is often the wrong starting point.

A more useful question is: what hormone-metabolism pattern made blood sugar unstable, cravings louder, belly fat more stubborn, and the body less responsive in the first place?

For some people, a GLP-1 is a reasonable tool while they work on correcting that pattern. For others, addressing the upstream hormonal drivers first reduces the need for medication entirely — or significantly improves results if medication is ultimately used. In many cases, the best clinical outcomes come from using the drug strategically while actively rebuilding the metabolic foundation underneath it.

GLP-1 medications can lower glucose and reduce appetite. They cannot restore muscle mass, normalize cortisol rhythm, improve thyroid conversion, or rebuild the metabolic flexibility that midlife hormonal shifts have eroded. That work still belongs to the individual — and it starts with understanding what pattern their body is actually running.

When we focus only on the medication, we treat blood sugar instability as an isolated problem to be managed. When we focus on the pattern, we see it for what it usually is: one visible symptom of a larger hormonal environment that shifted — gradually, predictably, and correctably.

The people who tend to do best, whether they use medication or not, are the ones who stop guessing and start understanding. They use medications and supplements as tools, not solutions. They ask better questions.

GLP-1 drugs can be powerful tools. But they are still tools. And tools work best when you know exactly what job you're asking them to do.

---

Your body didn't break. The rules changed.

Before you decide whether the next step is medication, nutrition, training, or deeper clinical work — understand the pattern your body is running right now. That's where the real answers are.

Find your hormone-metabolism pattern →

---

Dr. Jay Wrigley is a naturopathic doctor with over 30 years of clinical experience in hormone and metabolic medicine. He is the author of The Hormonal Blueprint and The 7-Day Protein Reset, and creator of the Hormone & Metabolism Pattern Assessment.